{"id":472,"date":"2018-07-24T17:26:24","date_gmt":"2018-07-24T15:26:24","guid":{"rendered":"https:\/\/sonnenscheinapotheke.de\/wpDrF2018\/?page_id=472"},"modified":"2026-02-09T16:45:40","modified_gmt":"2026-02-09T15:45:40","slug":"publikationen","status":"publish","type":"page","link":"https:\/\/drfresenpharma.de\/en\/home\/forschung\/publikationen\/","title":{"rendered":"Publications"},"content":{"rendered":"

Putzker M, Karapetyan I, Klose T.<\/strong> Leben retten – Blut spenden. PTA heute, Nr. 11, 27.05.2025<\/p>\n

Putzker M, Karapetyan I, Klose T.<\/strong> Alternativen zur klassischen Blutkonserve. PTA heute, Webcode W5TR9, 2025<\/p>\n

Jost R, Kespohl S, Kathrin E, Paulus-Tremel KE, F\u00fchrer F, Bonertz A, Sander I,\u00a0Klose T<\/strong>, Altin LM, Heller S, Heimke-Brinck R, D\u00f6rje F, Philippus S, Meyer M, Segebrecht S,Wessel T, Starke D, Sch\u00fclke S, Raulf M, Mahler. M\u00f6glichkeiten der Fertigstellung von Testallergenen in \u00f6ffebtlichen Apotheken zur Diagnostik von Typ I-Allergien \u2013 rechtliche Aspekte. Allergologie, Jahrgang 47, Nr. 7\/2024, S. 411-424<\/p>\n

Jost R, Kespohl S, Kathrin E, Paulus-Tremel KE, F\u00fchrer F, Bonertz A, Sander I, Klose T<\/b>, Altin LM, Heimke-Brinck R, D\u00f6rje F, Sch\u00fclke S, Raulf M, Mahler V.Validation of pharmacy standard operating procedures for preparation of Skin Prick test solutions (SPTs): Inter- & intra laboratory variability of Tyrophagus putrescentiae SPTs prepared at different sites. EAACI Congress Valencia 2024<\/p>\n

Jost R, Kespohl S, Sch\u00fclke S, Paulus-Tremel KE, F\u00fchrer F, Bonertz A, Sander I, Klose T<\/strong>, Altin LM, Heimke-Brinck R, D\u00f6rje F, Raulf M, Mahler V.
\nProduction of test allergens in public pharmacies for the diagnosis of occupational type I allergies: legal aspects and practical approach
\nMainzer Allergie Workshop 2024<\/p>\n

Jost R, Kespohl S, Paulus-Tremel K E, F\u00fchrer\u00a0 F, Bonertz\u00a0 A, Sander I, Klose T<\/strong>, Altin LM , Heimke-Brinck R, D\u00f6rje F, Raulf M, Mahler V.
\nFertigung von Testallergenen in \u00f6ffentlichen Apotheken zur Diagnose von berufsbedingten Typ I-Allergien: Rechtliche Aspekte und praktische Umsetzung (DGUV-Forschungsf\u00f6rderung, Projekt FB 317a)
\nDeutscher Allergiekongress, Bonn, 14.-16.09.2023<\/p>\n

S. Kespohl, R. Jost, I. Sander, S. Maryska, L.M. Altin,K. Paulus-Tremel, F. F\u00fchrer, A. Bonertz, T. Klose<\/strong>, T. Br\u00fcning, V. Mahler, M. Raulf.
\nQualit\u00e4tssicherung der Diagnostik von beruflichen Typ I-Allergien.
\n63. Jahrestagung der DGAUM, Jena, 16.03.2023<\/p>\n

S. Kespohl, R. Jost, I. Sander, S. Maryska, L.M. Altin,K. Paulus-Tremel, F. F\u00fchrer, A. Bonertz, T. Klose<\/strong>, T. Br\u00fcning, V. Mahler, M. Raulf.
\nQualit\u00e4tssicherung der Diagnostik von beruflichen Typ I-Allergien.
\n63. Jahrestagung der DGAUM, Jena, 16.03.2023<\/p>\n

Jost R, Kespohl S, Paulus-Tremel K, F\u00fchrer F, Bonertz A, Sander I, Altin L-M, Klose T, <\/strong>Raulf M, Mahler V.
\nExploring the possibility of in vivo test allergen-compounding in pharmacies: first results.
\nEAACI 2023<\/p>\n

Jost R, Kespohl S, Paulus-Tremel K, F\u00fchrer F, Bonertz A, Sander I, Altin L-M, Klose T, <\/strong>Raulf M, Mahler V.
\nTest allergens for occupational type I allergies \u2013 closing the diagnostic gaps?
\n34. Mainzer Allergie Workshop, 10.-11.03.2022<\/p>\n

Klose T.<\/strong>
\nEnde einer \u00c4ra? Patentfall Revlimid und T-rezept – was gibt es zu beachten?
\nMitteldeutscher H\u00e4matologie Dialog, Frankfurt, 01.03.2022<\/p>\n

Altin L-M, Klose T.<\/strong>
\nFallstricke der Pharmakotherapie in der Onkologie
\nSymposium Psychoonkologie, Supportivtherapie und ethische Fragen, Vallendar, 17.11.2021<\/p>\n

Putzker M, Dumitrescu M, Brillat M, Klose T.<\/strong>
\nBlutprodukte weltweit sicher gek\u00fchlt transportieren
\nManagement & Krankenhaus, 11\/2020-30<\/p>\n

Putzker M, Dumitrescu, Gandrabur T,\u00a0Klose T.<\/strong>
\nTransportul global \u00een sistem \u201efrigorific\u201c al produselor farmaceutice care necesit\u0103 refrigerare \u0219i congelare; 15 ani de experien\u021b\u0103 \u00een studii \u0219i practice
\nHEALTH, Anul 6, Revista Nr. 63, Aprilie-Mai 2019;18-20; ISBN 978-606-93639-2-8<\/p>\n

Klose T,<\/strong>\u00a0Putzker M.
\nPharmaceutical logistics with the premium system for cold chain transport of clinicals trials, drugs and blood products
\nIPL Forum, Schloss Braunfels, 14.05.2019<\/p>\n

Klose T<\/strong>, Putzker M.
\nTelepharmazie in \u00f6ffentlichen Apotheken in Deutschland – ein zukunftweisendes Modell?
\nSpringer Verlag, Apotheke und Marketing, 2018; 4-5 (https:\/\/www.apotheke-und-marketing.de\/telepharmazie-2160551-ma_article_recommend.html?)<\/p>\n

Putzker M, Dumitrescu M, Klose T<\/strong>.
\nGlobal cold chain transport of liquid and frozen pharmaceuticals: experience from 12 years of evaluation and daily routine.
\nFarmacia 2019, submitted for publication<\/p>\n

Putzker M, Tomaselli R, Klose T<\/strong>.
\nArbeitsschutz in \u00f6ffentlichen Apotheken im Licht der neuen Arbeitsmedizinischen Vorsorgeverordnung
\nSpringer Verlag, Apotheke und Marketing, 1-2017;11-14<\/em>
\n(http:\/\/www.apotheke-und-marketing.de\/arbeitsschutz-ganz-modern-1871151.html<\/a>)<\/p>\n

Klose T<\/strong>, von Deringer N, K\u00f6hl T, Lerchen C, Putzker M.
\nPatientenvorsorge – Ein Kurzrargeber.
\nVerlag Str\u00f6dicke 2017, 2.Auflage, 49 Seiten, ISBN 978-3-00-055527-5<\/em><\/p>\n

Klose T<\/strong>, Buchta O, Putzker M.
\nDrei Koblenzer entwickelten Smartphone-“app” f\u00fcr die individuelle medizinische Versorgung: Chance auf Lebensqualit\u00e4t und Einsparungen.
\nWatterich Verlag, TMK 2016; 26:40-1<\/em><\/p>\n

Klose T<\/strong>, Sarholz S, Himmerich S, Putzker M.
\nHilfe ein Kind- Ein Kurzrargeber f\u00fcr “Wartung und Pflege” – und dar\u00fcber hinaus.
\nVerlag Str\u00f6dicke 2016, 1. Auflage, 68 Seiten<\/em><\/p>\n

Klose T<\/strong>, Wolf M, Buchta O, Putzker M.
\niMedicplan for compliance: can it improve life?
\nEJOP 2016; 1\/ Vol. 10<\/em><\/p>\n

Klose T<\/strong>, Putzker M.
\nInternationaler Transport k\u00fchlkettenpflichtiger Arzneimittel unter Temperaturkonsistenz zur Umsetzung der aktuellen GDP-Richtlinie.
\nOnkologische Pharmazie, 18. Jahrgang; Nr. 02\/2016<\/em><\/p>\n

Woeste C, Klose T<\/strong>.
\nDie Einf\u00fchrung der Transportvalidierung.
\n8. NZW Dresden; 18.06.2016<\/em><\/p>\n

Putzker M, Tomaselli R, Klose T<\/strong>.
\nArbeitsschutz in \u00f6ffentlichen Apotheken im Licht der Arbeitsmedizinischen Versorgeverordnung.
\n8. NZW Dresden; 17.06.2016<\/em><\/p>\n

Klose T,<\/strong> Himmerich S, Putzker M, Zernack S, Trennheuser F.
\nErn\u00e4hrung und Hautpflege bei Krebs. Ein Kurzratgeber.
\nVerlag Str\u00f6dicke, 54 Seiten, 3. Auflage 07\/2015<\/em><\/p>\n

Klose T.<\/strong>
\nLOGISTICS with the \u201eBest system in the world\u201c for cold chain transport of clinical trials, drugs and blood products
\nDelta T Jahrestagung 21.\/22.04.2015<\/em><\/p>\n

Berger R, Dillender A, Domogalla K, Klose T<\/strong>, Nix U, Siedenkamp K.<\/strong>
\nWege zu positiver Krankheitsbew\u00e4ltigung und menschlichen Wachstum
\n12. Tagung; Brustzentrum Marienhaus Klinikum Neuwied; 21.02.2015<\/em><\/p>\n

Klose T<\/strong>, Putzker M.<\/strong>
\nChallenge for the new GDP policy: global validated cold chain transport (2-8\u00b0 C) of clinical trials and drugs
\nEJOP 2014; 4\/ Vol. 8<\/em><\/p>\n

Wolf M, Putzker M, Klose T<\/strong>.
\nSmartphone “app\u201c for Compliance: Better quality of life for patients and significant savings in health care.
\nASCO 2014<\/em><\/p>\n

Klose T<\/strong>, Schenk J, Putzker M.
\nNovel care conception for cancer patients in Germany.
\n31. Deutscher Krebskongress 2014<\/em><\/p>\n

Putzker M, Klose T.<\/strong>
\nWeltweit qualit\u00e4tsgesicherter Transport von Blutprodukten
\nSiemens Symposium W\u00fcrzburg, 20.06.2013<\/em><\/p>\n

Klose T<\/strong>, Bochert H H, Pruss A, Roth WK, Bohnen H, Putzker M.
\nA transport system for temperature-sensitive pharmaceuticals and especially red blood cell concentrates for use in widely varying physical and climatic conditions worldwide.
\nVox Sanguinis 2010;44-53<\/em><\/p>\n

Klose T<\/strong>, Prokoph B, Seidel K, Schmidt M, Hourfar K, Putzker M.
\nSafe system for transport of blood samples at recommended temperature (2-8\u00b0C).
\nClin. Lab. 2009;55:375-378<\/em><\/p>\n

Putzker M, Seidel K, Schmidt M, Hourfar K, Friedrich I, Bohnen H, Klose T.<\/strong>
\nTemperature-stable transport of blood products across Europe on varying environmental demand: finally working with fresh frozen plasma (FFP) as well.
\nClin. Lab. 2009;55:371-374<\/em><\/p>\n

Klose T<\/strong>, Prokoph B, Seidel K, Schmidt M, Hourfar K, Putzker M.
\nSafe system for transport of blood samples at recommended temperature (2-8\u00b0C).
\nTransfus Med Hemother 2009;36(suppl 1):63<\/em><\/p>\n

Hourfar K, Klose T<\/strong>, Putzker M, Sireis W, Gubbe K, Karl A, Tonn T, Mayr-Wohlfart U, Schrezenmeier H, Prokoph B, Ruester B, Seidel K, Hellmann I, Geusendam G, Siebert B, Seifried E, Schmidt M.
\nStability of transfusion transmitted viruses in whole blood.
\nTransfus Med Hemother 2009;36(suppl 1):12<\/em><\/p>\n

Putzker M, Seidel K, Schmidt M, Hourfar K, Friedrich I, Bohnen H, Klose T<\/strong>. Temperature-stable transport of blood products across Europe on varying environmental demand: finally working with fresh frozen plasma (FFP) as well.
\nTransfus Med Hemother 2009;36(suppl 1):63<\/em><\/p>\n

Klose T<\/strong>, Putzker M, Pru\u00df A, Fresen F, Borchert H-H.
\nTransport de produits pharmaceutiques: Un r\u00e9glement unique en Europe?
\nElsevier SAS: Actualit\u00e9s pharmaceutiques 2008;n\u00b0474:25-27<\/em><\/p>\n

Klose T<\/strong>, Putzker M, Pru\u00df A, Borchert H-H.
\nNovel System for worldwide qualified Transport of Red Blood Cells Concentrates (RBC) under Extreme Enviromental Conditions.
\nClin. Lab. 2008;54:25-28<\/em><\/p>\n

\u041a\u043b\u043e\u0437\u0435 T<\/strong>, \u041f\u0443\u0442\u0446\u043a\u0435\u0440 M, \u041f\u0440\u0443\u0441\u0441 A, \u0411\u043e\u0440\u0445\u0435\u0440\u0442 H-H.
\n\u0418\u0441\u043f\u043e\u043b\u044c\u0437\u043e\u0432\u0430\u043d\u0438\u0435 \u043f\u0430\u0441\u0441\u0438\u0432\u043d\u044b\u0445 \u043e\u0445\u043b\u0430\u0436\u0434\u0430\u044e\u0449\u0438\u0445 \u0431\u043e\u043ac\u043e\u0432 \u0434\u043b\u044f \u0442\u0440\u0430\u043d\u0441\u043f\u043e\u0440\u0442\u0438\u0440\u043e\u0432\u043a\u0438 \u043f\u0440\u043e\u0434\u0443\u043a\u0442\u043e\u0432 \u043a\u0440\u043e\u0432\u0438. \u0413ema\u0442o\u043bo\u0438\u044f \u0438 \u0442\u0440a\u043dc\u0444\u0443\u0437\u0438o\u043bo\u0433\u0438\u044f.
\n\u0418\u0437\u0434a\u0442e\u043b\u044cc\u0442\u0432\u043e \u201eMe\u0434\u0438\u0446\u0438\u043da\u201c, (\u044f\u043d\u0432\u0430\u0440\u044c), 33-35<\/em><\/p>\n

Putzker M, Klose T<\/strong>, S\u00f6nnichsen I, Eck D, Th\u00f6le A.
\nOptimierung der Hautantiseptik vor der Venenpunktion bei der Blutspende.
\nWehrmed. Mschr 2008; Heft 5-6:159-164<\/em><\/p>\n

Klose T<\/strong>, Putzker M, Pru\u00df A, Bochert H.-H.
\nNovel system for worldwide qualified transport of red blood cell concentrates (RBC) on extreme environmental demand.
\nTransfus Med Hemother 2007;34(suppl1):63<\/em><\/p>\n

Klose T<\/strong>, Wedekind K, Riggert J, van der Meer P-F, Heuft H-G, Perotti C.
\nTransfusionsmedizin: Aktuelles aus Forschung und Praxis.
\nTransfus Med Hemother 2006;33:544-45<\/em><\/p>\n

Klose T<\/strong>, Kiesewetter H, Pru\u00df A, Roth W-K, Bohnen H, Friedrich I, Eck D, Putzker M.
\nInfluence of below atmospheric pressure on the pharmaceutical quality of red blood cell concentrates (RBCs) during transport and storage.
\nClin. Lab. 2006;52:57-61<\/em><\/p>\n

Klose T<\/strong>, Pru\u00df A, Kiesewetter H, Roth W – K, Bohnen H, Putzker M.
\nQuality assurance for long lasting transports of red blood cell concentrates on extreme environmental demand.
\nTransfus Med Hemother 2004; 31:365-370<\/em><\/p>\n

Klose T<\/strong>, Bohnen H, Putzker M.
\nEnsuring the quality of red blood cells during long lasting transport on extreme environmental demand.
\nTransfus Med Hemother 2004; 31(suppl 3):43<\/em><\/p>\n

Klose T<\/strong>, Putzker M.
\nThalass\u00e4mie – Blut als Heilmittel.
\nPharmazeutische Zeitung 2003;148:38-39<\/em><\/p>\n

Skare J, Farley J, Strominger JL, Fresen KO<\/strong>, Cho MS, zur Hausen H<\/strong>.
\nTransformation by Epstein-Barr virus requires DNA sequences in the region of BamHI fragments Y and H.
\nJ Virol. 1985 Aug;55(2):286-97.<\/em><\/p>\n

Cho MS, Fresen KO<\/strong>, zur Hausen H<\/strong>.
\nMultiplicity-dependent biological and biochemical properties of Epstein-Barr virus (EBV) rescued from non-producer lines after superinfection with P3HR-1 EBV.
\nInt J Cancer. 1980 Sep 15;26(3):357-63.<\/em><\/p>\n

Bornkamm GW, Kaduk B, Kachel G, Schneider U, Fresen KO<\/strong>, Schwanitz G, Hermanek P.
\nEpstein-Barr virus-positive Burkitt’s lymphoma in a German woman during pregnancy.
\nBlut. 1980 Mar;40(3):167-77.<\/em><\/p>\n

Fresen KO<\/strong>, Cho MS, Gissmann L, zur Hausen H<\/strong>.
\nNC37-R1 Epstein-Barr virus (EBV): a possible recombinant between intracellular NC37 viral DNA and superinfecting P3HR-1 EBV.
\nIntervirology. 1980;12(6):303-10.<\/em><\/p>\n

zur Hausen H<\/strong>, Fresen KO<\/strong>.
\nHeterogeneity of Epstein-Barr virus.
\nBiochim Biophys Acta. 1979 Nov 30;560(3):343-53.<\/em><\/p>\n

Fresen KO<\/strong>, Cho MS, zur Hausen H<\/strong>.
\nRecovery of transforming EBV from non-producer cells after superinfection with non-transforming P3HR-1 EBV.
\nInt J Cancer. 1978 Oct 15;22(4):378-83.<\/em><\/p>\n

Fresen KO<\/strong>, Cho MS, zur Hausen H<\/strong>.
\nHeterogeneity of Epstein-Barr virus. IV. Induction of a specific antigen by EBV from two transformed marmoset cell lines in Ramos cells.
\nInt J Cancer. 1978 Aug 15;22(2):160-5.<\/em><\/p>\n

zur Hausen H<\/strong>, Fresen KO<\/strong>, Bornkamm GW.
\nEpstein-Barr virus genomes and their biological functions: a review.
\nIARC Sci Publ. 1978;(24 Pt 1):3-10.<\/em><\/p>\n

zur Hausen H<\/strong>, Fresen KO<\/strong>.
\nHeterogeneity of Epstein-Barr virus derived from P3HR-1 cells.
\nIARC Sci Publ. 1978;(20):391-6.<\/em><\/p>\n

Fresen KO<\/strong>.
\nBiologische und immunologische Untersuchungen zur Differenzierung von Epstein-Barr-Virusst\u00e4mmen
\nSpringer, 1978<\/em><\/p>\n

Heyden HW, Weber R, Stuckstedte H, Saal JG, Fresen KO<\/strong>.
\nIsoenzyme pattern of acid phosphatase in epstein-barr-virus-DNA positive permanent growing lymphoid cell lines (author’s transl).
\nBlut. 1977 Nov 22;35(5):395-404.<\/em><\/p>\n

zur Hausen H<\/strong>, Fresen KO<\/strong>.
\nHeterogeneity of Epstein-Barr virus. II. Induction of early antigens (EA) by complementation.
\nVirology. 1977 Aug;81(1):138-43.<\/em><\/p>\n

Fresen KO<\/strong>, Merkt B, Bornkamm GW, Hausen H.
\nHeterogeneity of Epstein-Barr virus originating from P3HR-1 cells. I. Studies on EBNA induction.
\nInt J Cancer. 1977 Mar 15;19(3):317-23.<\/em><\/p>\n

Fresen KO<\/strong>, zur Hausen H<\/strong>.
\nTransient induction of a nuclear antigen unrelated to Epstein-Barr nuclear antigen in cells of two human B-lymphoma lines converted by Epstein-Barr virus.
\nProc Natl Acad Sci U S A. 1977 Jan;74(1):363-6.<\/em><\/p>\n

Fresen KO<\/strong>, Hausen H.
\nEstablishment of EBNA-expressing cell lines by infection of Epstein-Barr virus (EBV)-genome-negative human lymphoma cells with different EBV strains.
\nInt J Cancer. 1976 Feb 15;17(2):161-6.<\/em><\/p>\n

Fresen KO<\/strong>, Illiger HJ.
\nLectin-independent, irreversible redistribution of concanavalin A receptors on influenza virus infected Ehrlich ascites tumor cells.
\nArch Gesamte Virusforsch. 1974;44(4):377-85.<\/em><\/p>\n

Fresen KO<\/strong>, D\u00fcbendorfer A.
\nElectrokinetic behavoir of Ehrlich ascites tumor cells following infection with oncolytic influenza viruses.
\nPathol Microbiol (Basel). 1974;40(3):227-8.<\/em><\/p>\n

Fresen KO<\/strong>.
\nPhysico-chemical changes of the cell surface of Ehrlich ascites tumour cells following infection with oncolytic influenza virus.
\nZentralbl Bakteriol Orig A. 1974;227(1-4):409-13.<\/em><\/p>\n

Fresen KO<\/strong>, D\u00fcbendorfer A.
\nPhysicochemical membrane changes in Ehrlich ascites tumor cells infected with oncolytic influenza virus.
\nArch Gesamte Virusforsch. 1973;41(3):267-76.<\/em><\/p>\n

Fresen KO<\/strong>, Vogt A.
\nUltrastructural localization of peroxidase-labelled nephrotoxic antibodies after intravenous application.
\nExp Pathol (Jena). 1973;8(4):276-82.<\/em><\/p>\n

Fresen KO<\/strong>, Vogt A.
\nHemolytic activity of antibody to sheep red cells conjugated to ferritin.
\nMed Microbiol Immunol. 1971;157(1):24-31.<\/em><\/p>\n

Moppert J, Fresen KO<\/strong>.
\nExperimental glomerulonephritis and glomerulonephrosis in the mouse following repeated ovalbumin injections. A light, fluroescence and electron microscopic study.
\nVirchows Arch Pathol Anat Physiol Klin Med. 1967;342(4):304-18.<\/em><\/p>\n

Fresen KO<\/strong>.
\nExperimentelle Glomerulonephritis und Glomerulonephrose bei der Maus nach wiederholten Ovalbumininjektionen: Eine licht-, fluoreszenz- u. elektronenoptische Untersuchung,
\nSpringer, 1967<\/em><\/p>\n

Skare J, Farley J, Strominger JL, Fresen KO<\/strong>, Cho MS, zur Hausen H<\/strong>.
\nTransformation by Epstein-Barr virus requires DNA sequences in the region of BamHI fragments Y and H.
\nJ Virol. 1985 Aug;55(2):286-97.<\/em><\/p>\n

Cho MS, Fresen KO<\/strong>, zur Hausen H<\/strong>.
\nMultiplicity-dependent biological and biochemical properties of Epstein-Barr virus (EBV) rescued from non-producer lines after superinfection with P3HR-1 EBV.
\nInt J Cancer. 1980 Sep 15;26(3):357-63.<\/em><\/p>\n

Bornkamm GW, Kaduk B, Kachel G, Schneider U, Fresen KO<\/strong>, Schwanitz G, Hermanek P.
\nEpstein-Barr virus-positive Burkitt’s lymphoma in a German woman during pregnancy.
\nBlut. 1980 Mar;40(3):167-77.<\/em><\/p>\n

Fresen KO<\/strong>, Cho MS, Gissmann L, zur Hausen H<\/strong>.
\nNC37-R1 Epstein-Barr virus (EBV): a possible recombinant between intracellular NC37 viral DNA and superinfecting P3HR-1 EBV.
\nIntervirology. 1980;12(6):303-10.<\/em><\/p>\n

zur Hausen H<\/strong>, Fresen KO<\/strong>.
\nHeterogeneity of Epstein-Barr virus.
\nBiochim Biophys Acta. 1979 Nov 30;560(3):343-53.<\/em><\/p>\n

Fresen KO<\/strong>, Cho MS, zur Hausen H<\/strong>.
\nRecovery of transforming EBV from non-producer cells after superinfection with non-transforming P3HR-1 EBV.
\nInt J Cancer. 1978 Oct 15;22(4):378-83.<\/em><\/p>\n

Fresen KO<\/strong>, Cho MS, zur Hausen H<\/strong>.
\nHeterogeneity of Epstein-Barr virus. IV. Induction of a specific antigen by EBV from two transformed marmoset cell lines in Ramos cells.
\nInt J Cancer. 1978 Aug 15;22(2):160-5.<\/em><\/p>\n

zur Hausen H<\/strong>, Fresen KO<\/strong>, Bornkamm GW.
\nEpstein-Barr virus genomes and their biological functions: a review.
\nIARC Sci Publ. 1978;(24 Pt 1):3-10.<\/em><\/p>\n

zur Hausen H<\/strong>, Fresen KO<\/strong>.
\nHeterogeneity of Epstein-Barr virus derived from P3HR-1 cells.
\nIARC Sci Publ. 1978;(20):391-6.<\/em><\/p>\n

Fresen KO<\/strong>.
\nBiologische und immunologische Untersuchungen zur Differenzierung von Epstein-Barr-Virusst\u00e4mmen
\nSpringer, 1978<\/em><\/p>\n

Heyden HW, Weber R, Stuckstedte H, Saal JG, Fresen KO<\/strong>.
\nIsoenzyme pattern of acid phosphatase in epstein-barr-virus-DNA positive permanent growing lymphoid cell lines (author’s transl).
\nBlut. 1977 Nov 22;35(5):395-404.<\/em><\/p>\n

zur Hausen H<\/strong>, Fresen KO<\/strong>.
\nHeterogeneity of Epstein-Barr virus. II. Induction of early antigens (EA) by complementation.
\nVirology. 1977 Aug;81(1):138-43.<\/em><\/p>\n

Fresen KO<\/strong>, Merkt B, Bornkamm GW, Hausen H.
\nHeterogeneity of Epstein-Barr virus originating from P3HR-1 cells. I. Studies on EBNA induction.
\nInt J Cancer. 1977 Mar 15;19(3):317-23.<\/em><\/p>\n

Fresen KO<\/strong>, zur Hausen H<\/strong>.
\nTransient induction of a nuclear antigen unrelated to Epstein-Barr nuclear antigen in cells of two human B-lymphoma lines converted by Epstein-Barr virus.
\nProc Natl Acad Sci U S A. 1977 Jan;74(1):363-6.<\/em><\/p>\n

Fresen KO<\/strong>, Hausen H.
\nEstablishment of EBNA-expressing cell lines by infection of Epstein-Barr virus (EBV)-genome-negative human lymphoma cells with different EBV strains.
\nInt J Cancer. 1976 Feb 15;17(2):161-6.<\/em><\/p>\n

Fresen KO<\/strong>, Illiger HJ.
\nLectin-independent, irreversible redistribution of concanavalin A receptors on influenza virus infected Ehrlich ascites tumor cells.
\nArch Gesamte Virusforsch. 1974;44(4):377-85.<\/em><\/p>\n

Fresen KO<\/strong>, D\u00fcbendorfer A.
\nElectrokinetic behavoir of Ehrlich ascites tumor cells following infection with oncolytic influenza viruses.
\nPathol Microbiol (Basel). 1974;40(3):227-8.<\/em><\/p>\n

Fresen KO<\/strong>.
\nPhysico-chemical changes of the cell surface of Ehrlich ascites tumour cells following infection with oncolytic influenza virus.
\nZentralbl Bakteriol Orig A. 1974;227(1-4):409-13.<\/em><\/p>\n

Fresen KO<\/strong>, D\u00fcbendorfer A.
\nPhysicochemical membrane changes in Ehrlich ascites tumor cells infected with oncolytic influenza virus.
\nArch Gesamte Virusforsch. 1973;41(3):267-76.<\/em><\/p>\n

Fresen KO<\/strong>, Vogt A.
\nUltrastructural localization of peroxidase-labelled nephrotoxic antibodies after intravenous application.
\nExp Pathol (Jena). 1973;8(4):276-82.<\/em><\/p>\n

Fresen KO<\/strong>, Vogt A.
\nHemolytic activity of antibody to sheep red cells conjugated to ferritin.
\nMed Microbiol Immunol. 1971;157(1):24-31.<\/em><\/p>\n

Moppert J, Fresen KO<\/strong>.
\nExperimental glomerulonephritis and glomerulonephrosis in the mouse following repeated ovalbumin injections. A light, fluroescence and electron microscopic study.
\nVirchows Arch Pathol Anat Physiol Klin Med. 1967;342(4):304-18.<\/em><\/p>\n

Fresen KO<\/strong>.
\nExperimentelle Glomerulonephritis und Glomerulonephrose bei der Maus nach wiederholten Ovalbumininjektionen: Eine licht-, fluoreszenz- u. elektronenoptische Untersuchung,
\nSpringer, 1967<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

Putzker M, Karapetyan I, Klose T. Leben retten – Blut spenden. PTA heute, Nr. 11, 27.05.2025 Putzker M, Karapetyan I, Klose T. Alternativen zur klassischen Blutkonserve. PTA heute, Webcode W5TR9, 2025 Jost R, Kespohl S, Kathrin E, Paulus-Tremel KE, F\u00fchrer… <\/p>\n","protected":false},"author":1,"featured_media":0,"parent":466,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_locale":"en_US","_original_post":"76","footnotes":""},"class_list":["post-472","page","type-page","status-publish","hentry","en-US"],"_links":{"self":[{"href":"https:\/\/drfresenpharma.de\/wp-json\/wp\/v2\/pages\/472","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/drfresenpharma.de\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/drfresenpharma.de\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/drfresenpharma.de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/drfresenpharma.de\/wp-json\/wp\/v2\/comments?post=472"}],"version-history":[{"count":5,"href":"https:\/\/drfresenpharma.de\/wp-json\/wp\/v2\/pages\/472\/revisions"}],"predecessor-version":[{"id":1005,"href":"https:\/\/drfresenpharma.de\/wp-json\/wp\/v2\/pages\/472\/revisions\/1005"}],"up":[{"embeddable":true,"href":"https:\/\/drfresenpharma.de\/wp-json\/wp\/v2\/pages\/466"}],"wp:attachment":[{"href":"https:\/\/drfresenpharma.de\/wp-json\/wp\/v2\/media?parent=472"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}